GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify where the stock now trades.
The pharmaceutical giant currently trades at approximately 15.5x earnings, a figure that sits well below the broader pharmaceuticals industry average of around 21.8x.
That discount deepens further when compared against a wider peer group, which trades at roughly 45.0x earnings, suggesting the market is applying a meaningfully lower multiple to GSK than to many comparable drug makers.
A fair multiple model that adjusts for growth prospects, profitability, and risk points to a higher P/E than where GSK currently trades, causing the shares to screen as undervalued on that particular measure.
Recent deals in cancer therapies, including new T cell engager and antibody conjugate programs, represent significant research and development commitments that may shape future profit streams and investor sentiment.
Despite that pipeline investment, the current P/E still prices GSK below both its sector benchmark and broader peer reference points, which leaves room for debate about whether the discount is warranted or excessive.
Community opinion on GSK’s valuation remains divided, with bulls pointing to pipeline reinvestment as underappreciated and bears arguing that legal and pricing risks carry more weight than the market currently reflects.
The bull case frames GSK as roughly 14% undervalued, citing “strong volume growth in key high-margin areas like oncology (Jemperli, Blenrep), immunology (Benlysta, Nucala, depemokimab), and HIV (long-acting injectables)” as evidence of the company’s ability to capture premium pricing and support margin expansion.
The bear case places GSK at approximately 28% overvalued, warning that “increasing legal liabilities, particularly ongoing Zantac litigation and potential new claims related to vaccine adverse events, will result in substantial settlement outflows and unplanned expenses, further pressuring free cash flow.”
Those competing narratives highlight just how much the stock’s next move hinges on which version of GSK’s future ultimately materializes across oncology, immunology, and its HIV franchise.
Investors considering the P/E story should also weigh additional risk markers that could materially alter the overall valuation picture before drawing firm conclusions about where the shares stand today.
The gap between GSK’s current earnings multiple and those of its industry peers remains the central tension for anyone trying to determine whether the stock’s ongoing run still has room to extend or is nearing its limits.
